Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMYMP) EBT (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed EBT for 17 consecutive years, with $1.5 billion as the latest value for Q4 2025.

  • Quarterly EBT rose 740.0% to $1.5 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.3 billion through Dec 2025, up 211.33% year-over-year, with the annual reading at $9.3 billion for FY2025, 211.33% up from the prior year.
  • EBT for Q4 2025 was $1.5 billion at Bristol Myers Squibb, down from $3.1 billion in the prior quarter.
  • The five-year high for EBT was $3.1 billion in Q3 2025, with the low at -$11.5 billion in Q1 2024.
  • Average EBT over 5 years is $1.3 billion, with a median of $1.9 billion recorded in 2021.
  • The sharpest move saw EBT surged 932.24% in 2021, then crashed 515.74% in 2024.
  • Over 5 years, EBT stood at $1.9 billion in 2021, then rose by 0.05% to $1.9 billion in 2022, then fell by 9.95% to $1.7 billion in 2023, then tumbled by 89.55% to $175.0 million in 2024, then skyrocketed by 740.0% to $1.5 billion in 2025.
  • According to Business Quant data, EBT over the past three periods came in at $1.5 billion, $3.1 billion, and $1.8 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.